GSK’s Penmenvy, Bavarian Nordic’s Vimkunya Clear US FDA, Will CDC Follow?

 
• By Bridget Silverman

The US FDA approval of new meningococcal and chikungunya vaccines arrived in time for the 26-28 February meeting of the CDC’s Advisory Committee On Immunization Practices, if political developments allow.

The next step for newly FDA-approved vaccines is usually the CDC Advisory Committee on Immunization Practices, but the fate of a scheduled meeting is unclear. (Shutterstock)

More from Vaccines

More from Regulatory Trackers